JPMorgan initiated coverage of Ceribell (CBLL) with an Overweight rating and $32 price target Ceribell has developed a ...

Behind the Bell is an interview series featuring CEOs, executives or founders, live from MarketSite on a company’s listing day or milestone celebration—generally in the moments after ringing ...

J.P. Morgan started Ceribell (CBLL) with an overweight rating, pointing to its recurring revenue business model with a gross ...

Ceribell, Inc. is a commercial-stage medical technology company, which focuses on transforming the diagnosis and management of patients with serious neurological conditions. Its products include ...

Analyst Josh Jennings of TD Cowen maintained a Buy rating on Ceribell, Inc. (CBLL – Research Report), boosting the price target to $36.00. Pick the best stocks and maximize your portfolio ...

Shares of CeriBell (NASDAQ:CBLL – Get Free Report) have earned a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Six analysts have ...

TD Cowen analyst Joshua Jennings raised the firm’s price target on Ceribell (CBLL) to $36 from $31 and keeps a Buy rating on the shares. The firm said its target increase reflects a slightly ...

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients ...

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients ...

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ...